Mouse models of hepatocarcinogenesis: What can we learn for the prevention of human hepatocellular carcinoma? by Vucur, Mihael et al.
www.impactjournals.com/oncotarget/  Oncotarget, September, Vol.1, No 5
Oncotarget 2010; 1:  373 - 378 www.impactjournals.com/oncotarget 373
Mouse models of hepatocarcinogenesis: What can we learn for 
the prevention of human hepatocellular carcinoma?
Mihael Vucur1,*, Christoph Roderburg1,*, Kira Bettermann1, Frank Tacke1, Mathias 
Heikenwalder2, Christian Trautwein1 and Tom Luedde1
1 Department of Internal Medicine III, University Hospital of RWTH Aachen, D- 52074 Aachen, Germany
2 Institute of Virology, Technical University München, Helmholtz Center München, D-81675 Munich, Germany
* Equal contribution
Correspondence to: Tom Luedde, M.D./Ph.D., e-mail: tluedde@ukaachen.de
Κeywords: HCC, mouse models, TAΚ1, DEN, inflammation, signaling
Received: July 27, 2010, Accepted: August 8, 2010, Published: September 13, 2010
Copyright: © Vucur et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
AbstrAct:
	 There	is	growing	evidence	that	chronic	inflammatory	processes	are	involved	in	
triggering	the	sequence	from	chronic	liver	injury	to	liver	fibrosis,	ultimately	leading	to	
liver	cancer.	In	the	last	years	this	process	has	been	recapitulated	in	a	growing	number	
of different mouse models. However, it has remained unclear whether and how these 
mouse	models	reflect	the	clinical	reality	of	human	hepatocellular	carcinoma	(HCC).	
  Research with animal models but also human liver specimens has indicated 
that	 the	 NF-κB	 signaling	 pathway	 might	 withhold	 a	 crucial	 function	 in	 the	
mediation	of	chronic	hepatic	inflammation	and	the	transition	to	HCC	in	humans.	
However,	 previous	 studies	 led	 to	 divergent	 and	 partly	 conflicting	 results	 with	
regards	to	the	functional	role	of	NF-κB	in	hepatocarcinogenesis.	Here,	we	discuss	
a	 new	 genetic	 mouse	 model	 for	 HCC,	 the	 liver-specific	 TAK1	 knockout	 mouse,	
which	 lacks	 the	 NF-κB	 activating	 kinase	 TAK1	 specifically	 in	 parenchymal	 liver	
cells.	 Molecular	 findings	 in	 this	 mouse	 model	 and	 their	 possible	 significance	 for	
chemopreventive strategies against HCC are compared to other murine HCC models. 
Hepatocellular carcinoma (HCC) represents the 
most common primary carcinoma of the liver [1]. In most 
instances, HCC arises in a setting of chronic inflammation 
and  subsequent  liver  fibrosis  [2].  Besides  chronic 
alcohol consumption or drug abuse, autoimmunity or 
the uptake of liver toxins (e.g. Aflatoxin B1), infections 
with Hepatitis B- (HBV) and Hepatitis C-viruses (HCV) 
represent the main risk-factors for hepatocarcinogenesis 
[3, 4]. The world-wide spread of HBV and HCV not only 
in developing but also in industrialized countries has led 
to approximately 500 million people persistently infected 
with HBV or HCV. This resulted in a strong rise in HCC-
incidence. Consequently, HCC is the 5th most common 
cause for cancer related death world-wide; in some African 
or Asian countries HCC is even the first common cause for 
cancer related morbidity [3, 4]. In addition to its enormous 
clinical relevance, its unique pathophysiological features 
have  made  liver  cancer  research  a  field  for  studying 
basic molecular and cellular events driving chronic 
inflammation  induced  carcinogenesis,  a  process  whose 
molecular underpinnings have largely remained elusive. 
Based  on  the  wide  range  of  these  features,  including 
immunology, tumor biology, genetics, metabolomics, 
cell biology etc., basic scientists from various research 
fields have focused their interest on the examination of 
animal HCC models. This will hopefully accelerate the 
discovery of new molecular mechanisms involved in 
hepatocarcinogenesis,  subsequently  leading  to  novel  - 
urgently needed - therapeutic strategies against HCC. 
Only recently, small inhibitor molecules have 
entered clinical practice to treat patients suffering from 
HCC. As such, Sorafenib (Nexavar®) is one of the 
new therapeutic agents that inhibit both pro-angiogenic 
(VEGFR-1,  -2,  -3;  PDGFR-β)  and  tumorigenic  (RET, 
Flt-3, c-Kit) receptor tyrosine kinases. Its efficacy in the 
context of HCC treatment was demonstrated in two large 
phase III clinical trials (SHARP and Asia-Pacific trial), 
which were conducted in both Western and Asian countries 
[5, 6]. Besides sorafenib, further therapeutic agents like Oncotarget 2010; 1:  373 - 378 374 www.impactjournals.com/oncotarget
regorafenib (BAY 73-4506) are currently investigated for 
their potential as anti-liver cancer therapeutics. 
However, these new therapeutics “only” prolong 
survival and are palliative, while substances that could be 
used in an adjuvant setting are still lacking. In addition, 
it has to be clearly stated that HCC represent a diverse 
spectrum of cancers that will likely need - depending on 
the  tumor  type  and  tumor  stage  -  different  therapeutic 
strategies. In summary, systemic therapeutic options for 
HCC treatment are currently limited, underlining the need 
for new molecular targets. As outlined above, it has been 
well established that chronic inflammation and fibrosis 
precedes hepatocarcinogenesis. The eradication of the 
most  common  cause  of  chronic  hepatic  inflammation 
in humans (infection with HBV and HCV) is currently 
unattainable.  Therefore,  identification  of  central 
inflammatory signaling pathways that drive the transition 
from chronic liver injury to dysplasia and HCC might 
indeed open new possibilities for HCC-chemoprevention 
in a setting of chronic hepatitis. 
In order to gain a better functional insight into the 
molecular mechanisms of hepatocarcinogenesis, multiple 
studies were performed using human HCC tissue. In 
the last years, a collection of genetic and epigenetic 
alterations, chromosomal aberrations, gene mutations and 
altered molecular pathways was described [7]. As such, 
chromosomal alterations could be attributed to certain 
genes potentially involved in hepatocarcinogenesis, such 
as c-Myc (8q), Cyclin A2 (4q), Cyclin D1 (11q), Rb1 
(13q),  AXIN1  (16p),  p53  (17p),  IGFR-II/M6PR  (6q), 
p16  (9p),  E-Cadherin  (16q),  SOCS  (16p),  and  PTEN 
(10q) [7, 8]. Further, chromosomal alterations could be 
described in HCC, of which amplifications of 1q (58%-
78%), 6p, 8q, 17q, and 20q, and deletions in 4q, 8p, 13q, 
16q, and 17p represented the most frequent ones [9, 10]. 
However, in many cases it was difficult to assess whether 
these alterations represented a correlative epiphenomenon 
or if they were causally linked to HCC pathogenesis. In 
the light of the apsects mentioned above animal-models 
for HCC offer a unique possibility to study mechanistic 
and cellular aspects of tumor biology, including genetics 
of tumor initiation and promotion, tumor progression 
and spreading (metastasis) in vivo.  Moreover,  animal 
models  also  represent  a  valuable  tool  to  pre-screen 
various therapeutic compounds for their efficacy to inhibit 
particular signaling pathways and prevent or decelerate 
HCC development. 
The  fact  that  inflammatory  stimuli  promote  HCC 
development has been recapitulated in various rodent 
models and indeed during the last decades different 
models of chronic or acute liver damage induced 
carcinogenesis (e.g. chemically or genetically) have 
been established. One of the best studied chemically 
induced  HCC-models  is  the  diethylnitrosamine  (DEN) 
induced liver carcinogenesis, which has been established 
in rats and mice [11]. In mice, a single dose of DEN at 
the  age  of  2  weeks  causes  DNA-damage,  subsequent 
acute hepatitis, finally leading to HCC at approximately 
8-10 months of age. The DEN rodent model withholds 
several advantages: (1) it can easily be administered to 
mice from different genetic backgrounds and of different 
genotype, (2) it has a high HCC incidence and (3) is highly 
reproducible  [12].  Moreover,  liver  tumors  from  these 
mice withhold important features of a malignant cancer, 
since they metastasize in the lung. However, the primary 
event  in  DEN-induced  carcinogenesis  is  DNA-damage 
leading to genetic mutations in an otherwise healthy 
liver.  This  indicates  that  -  although  happening  in  the 
context of acute liver damage - the sequence of primary 
DNA-damage  and  secondary  acute  inflammation  does 
not quite reproduce the clinical reality of most patients, 
which develop HCC on the basis of chronic hepatitis in 
the absence of mutagens. Still, the DEN-rodent model has 
revealed crucial molecular and cellular pathways involved 
in the development of liver cancer and is a valuable tool 
to investigate particular molecules for their potential in 
inhibiting or promoting liver cancer formation [12-14].
In  contrast  to  the  DEN-rodent  model,  the  Mdr2-
knockout mouse represents a prototype of a genetically 
modified  mouse  model  used  to  identify  the  pathways 
responsible  for  chronic  inflammation-induced  liver 
cancer.  Mdr2-knockout  mice  lack  a  biliary  transporter 
protein denoted as multi-drug resistance gene 2 (mdr2) 
leading to cholestatic hepatitis and liver cancer [15]. 
Tumor  development  in  the  Mdr2-knockout  mice 
progresses  through  distinct  phases:  inflammation, 
dysplasia, dysplastic nodules, carcinoma and metastasis, 
thus mimicking to some degree the formation of HCC 
in  humans  [16].  A  similar  sequence  of  inflammation, 
mild fibrosis, dysplasia and HCC formation is observed 
in  transgenic  mice  that  overexpress  the  inflammatory 
cytokines lymphotoxin a and b (LTab) in the liver 
(AlbLTab)  [17].  It  was  demonstrated  that  lymphotoxin 
LTa, b and their receptor (LTbR) are upregulated in livers 
of humans with HBV- or HCV-induced hepatitis and HCC. 
Subsequently,  liver-specific  LTab  expression  in  mice 
induced liver inflammation and HCC [17]. In this context 
it is important to note that blockage of LTbR signaling 
strongly reduced the incidence of chronic hepatitis as well 
as abolished liver cancer [17].
The differences between the above mentioned 
rodent  HCC-models  are  reflected  by  distinct,  activated 
inflammatory signaling pathways leading to inflammation 
and hepatocarcinogenesis. One of the most important 
and  best-studied  inflammatory  signaling  cascades 
involved is - indeed - the NF-kB pathway. NF-kB can 
be activated by different stimuli like tumor necrosis 
factor  or  Interleukin-1  and  controls  the  transcription 
of  inflammatory  and  anti-apoptotic  genes  [18].  One 
important step in the activation of NF-kB is represented 
by activation of a high-molecular-weight kinase complex, 
the so-called IKK complex, consisting of two catalytic Oncotarget 2010; 1:  373 - 378 375 www.impactjournals.com/oncotarget
subunits, IKK1 (IKKa) and IKK2 (IKKb), as well as a 
regulatory subunit called NEMO (IKKg). Upon activation 
of this pathway by TNF, the IKK complex is recruited to 
adaptor proteins like TRAF2 and RIP1 and is activated by 
the kinase TAK1, so it can phosphorylate the inhibitory 
protein IkBa and mediate nuclear translocation of NF-
kB (Fig. 1). In the DEN-rodent model, inhibition of NF-
kB by conditional liver specific deletion of IKK2 led to 
increased liver-tumor formation [19], suggesting that the 
proinflammatory  NF-kB  signaling  pathway  suppresses 
hepatocarcinogenesis. In contrary, inhibition of the NF-
kB signaling in the Mdr2-knockout mouse led to a strong 
decrease in hepatocarcinogenesis compared to mice 
with  proficient  NF-kB  signaling,  arguing  for  a  tumor-
promoter-function of this pathway [16]. Similarly, lack of 
NF-kB signaling strongly decreased chronic hepatitis and 
prevented hepatocarciniogenesis in the LT ab liver-tumor 
model, with the only difference that liver tumor formation 
also occurred in the absence of TNFR1 [17]. The reason 
for this obvious contradiction between the different 
murine HCC models has not been solved, meaning that 
it is presently not clear if NF-kB inhibition might be an 
option for chemoprevention of hepatocellular carcinoma 
in  humans.  Possibly,  suppression  of  NF-kB  signaling 
might be only beneficial for particular subtypes of human 
HCC – but this will need further investigation.
 How can this contradictory role of IKKb signaling 
in HCC formation be reconciled? On the one hand IKKb 
signaling might be required for hepatocytes to respond to 
and survive carcinogenic stimuli and acute liver injury 
(e.g. DEN exposure). On the other hand, IKKb signaling 
might enable local chemokine expression by hepatocytes 
subsequently leading to chronic inflammation and HCC 
(e.g. like in the AlbLTab mouse model). Consistent with 
this hypothesis is the finding that AlbLTab x Rag1-/- mice 
were devoid of chronic hepatitis, hepatocyte or oval-cell 
proliferation and failed to develop HCC. 
Why could immune cells be essential for liver 
tumorigenesis? One explanation would be that CD4+ or 
CD8+  T-cells  expressing  inflammatory  cytokines  (e.g. 
IL1b,  TNF,  IFNg)  as  well  as  cytolytic  proteins  (e.g. 
Granzyme B) might contribute to hepatocyte cell death 
and tissue remodeling and transformation, finally leading 
to HCC [20]. Consequently, the role of NF-kB signaling 
in hepatocarcinogenesis might depend on the mouse 
model and the type or degree of liver inflammation and 
injury [21].
To  further  dissect  the  role  of  NF-kB  in 
hepatocarcinogenesis we recently studied the roles of the 
molecules  NEMO  and  TAK1  in  hepatocarcinogenesis 
[22].  As  mentioned  above,  both  of  these  molecules 
are  involved  in  controlling  the  activation  of  NF-kB  in 
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Figure 1: Activation of canonical NF-κB signaling by TNF-α. Association of TNF-R1 results in TRADD-dependent TRAF2 and 
RIP1 recruitment. TRAF2 mediates K63-linked ubiquitination of RIP1 and recruits the IKK complex via the catalytic subunit NEMO. 
Autoubiquitination of TRAF2 causes TAK1 activation by interaction via TAB2/3. In cosequence TAK1 phosphorylate and activate IKKβ, 
which in turn phosphorylate IκBα, leading to his proteasomal degradation and releases NF-κB.Oncotarget 2010; 1:  373 - 378 376 www.impactjournals.com/oncotarget
various  cellular  systems  [22-24]  and  are  important  in 
mediating inflammatory signaling pathways. Surprisingly, 
conditional  deletion  of  NEMO  as  well  as  TAK1  in 
hepatocytes (referred to as NEMOLPC-KO and TAK1LPC-KO 
mice)  leads  to  spontaneous  HCC-development  in  mice 
(Fig. 2A). Hepatocarcinogenesis was preceded by hepatic 
inflammation and liver cirrhosis which progresses through 
distinct phases (hepatitis, liver fibrosis and dysplasia) to 
HCC (Fig. 2B). These findings support the hypothesis that 
at least some members of the NF-kB pathway function 
as a tumor suppressors, and our further results suggested 
that this mainly confers to IKK subunits and molecules 
upstream of the IKK-complex. However, it is presently 
unclear if these new genetic tumor models mirror any 
entity of human HCC. 
HCC  of  TAK1LPC-KO  and  NEMOLPC-KO mice 
were investigated in further detail on genomic 
and transcriptional level. Therefore, we compared 
chromosomal  aberrations  in  micro-dissected  tumors  of 
TAK1LPC-KO and NEMOLPC-KO mice. Comparative genomic 
hybridization  analysis  (aCGH)  revealed  that  all  liver 
tumors seen in NEMOLPC-KO mice displayed chromosomal 
amplifications  in  a  more  or  less  random  manner  (data 
not  shown).  In  contrast,  TAK1LPC-KO mice displayed 
defined chromosomal amplifications within certain hot-
spot-areas  on  chromosomes  4,  8  and  13  [22].  These 
amplifications  and  deletions  of  chromosomal  regions 
ranged from 0.68 megabase (MB) to 151 MB in TAK1LPC-
KO tumors and correlated with increased transcription of 
certain oncogenes located within the respective amplified 
chromosomal  regions:  Ntrk2,  Net1  and  Jun.  These 
findings suggest completely different pathomechanisms 
of hepatocarcinogenesis between the TAK1- and NEMO-
models: Although both mice show a defective NF-kB-
activation in hepatocytes, only one model is associated 
with  defined  aberrations  within  certain  chromosomal 
loci, upregulation of particular oncogenes as well as 
different histopathological features. This underlines that 
currently unknown molecular pathways downstream 
of TNF-associated molecules exist which might couple 
inflammation with specific genetic alterations as the basis 
for malignant transformation of hepatocytes. In this light, 
the new TAK1 model might represent an attractive model 
for a deeper understanding of these complex processes in 
Figure 2: (A) Representative macroscopic pictures of 7-9 weeks-old male WT (left panel), TAK1LPC-KO (middle panel) and 
NEMOLPC-KO livers (right panel). Histological features of liver tumors in TAK1LPC-KO and NEMOLPC-KO mice stained by H/E (lower panel, 
arrow head). TAK1LPC-KO liver showed a clear cell HCC whereas NEMOLPC-KO showed an eosinophilic, hepatoid HCC. (B) Serum level 
analysis of alanine aminotransferase (ALT), aspartate aminotransferase (AST). Results are shown as mean, error bars indicate SEM. **P<0.01, 
***P<0.001 (n=5 each genotype).
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the future, which might lead to a new chemopreventive 
strategy in patients with chronic hepatitis. 
Given  the  rising  number  of  genetic  or  chemical 
murine HCC models, the question remains if all these 
models are of significance for the understanding of human 
hepatocarcinogenesis and which of these models reflect 
which type of HCC in patients. This question could be 
addressed by a more systematic approach to compare 
specific  molecular  and  genetic  features  between  the 
different murine HCC models. As such, chromosomal 
aberrations in the various murine models, histopathology, 
transcriptional and metabolic changes could be compared 
at different stages of tumor initiation and promotion and 
correlated with the development of HCC in cirrhotic 
transformed livers. The same applies to signalome and 
transcriptome analyses or the possible role of hepatic stem 
cells during tumorigenesis. 
The absence of a curative pharmacological treatment 
approach for human HCC and the limitations of the present 
molecular inhibitors in the palliative situation clearly 
underline the need for the identification of novel target 
molecules.  The  unique  inflammation-  carcinogenesis 
sequence  in  HCC  suggest  that  such  specific  inhibitors 
against inflammatory signaling pathways may allow to 
intercept the continious transition from chronic liver 
injury to HCC. A systematic analysis of the various 
available murine liver cancer models might be the basis 
for the future identification of these potential targets and 
might open the door to the successful chemoprevention 
against liver cancer. 
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